Document is current
Any future updates will be listed below
-
Authors
Faget, Julien
Peters, Solange
Quantin, Xavier
Meylan, Etienne
Bonnefoy, Nathalie
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01688206 at ClinicalTrials.govnct02501096 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Neutrophils in the era of immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-002242
nct01472081 at ClinicalTrials.govDocuments that mention this clinical trial
Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma
https://doi.org/10.1080/14737140.2019.1573678
2 Efficacy and safety of lenvatinib plus pembrolizumab in patients with previously treated ovarian cancer in the multicohort phase 2 LEAP-005 study
https://doi.org/10.1136/ijgc-2020-igcs.2
Update on the Biology and Management of Renal Cell Carcinoma
https://doi.org/10.1136/jim-2018-000918
354 Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study
https://doi.org/10.1136/jitc-2021-sitc2021.354
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update
https://doi.org/10.1200/jco.22.01021
Neutrophils in the era of immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-002242
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146
https://doi.org/10.1136/jitc-2023-007929
297 Leap-005: evaluating the safety and efficacy of lenvatinib and pembrolizumab in patients previously treated for ovarian cancer, a multi-cohort phase 2 study
https://doi.org/10.1136/ijgc-2020-esgo.116
nct04139317 at ClinicalTrials.govDocuments that mention this clinical trial
Neutrophils in the era of immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-002242
nct04050462 at ClinicalTrials.govDocuments that mention this clinical trial
Neutrophils in the era of immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-002242
nct03631407 at ClinicalTrials.govDocuments that mention this clinical trial
Neutrophils in the era of immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-002242
nct03184870 at ClinicalTrials.govDocuments that mention this clinical trial
<i>CCR5</i> and <i>CCL5</i> gene expression in colorectal cancer: comprehensive profiling and clinical value
https://doi.org/10.1136/jitc-2023-007939
Neutrophils in the era of immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-002242
nct02826486 at ClinicalTrials.govDocuments that mention this clinical trial
1282 Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types
https://doi.org/10.1136/jitc-2022-sitc2022.1282
Circulating tumour cell clusters: isolation, biological significance and therapeutic implications
https://doi.org/10.1136/bmjonc-2024-000437
<i>CCR5</i> and <i>CCL5</i> gene expression in colorectal cancer: comprehensive profiling and clinical value
https://doi.org/10.1136/jitc-2023-007939
Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer
https://doi.org/10.1136/jitc-2024-011284
Neutrophils in the era of immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-002242
CCR5 and CCL5 in metastatic colorectal cancer
https://doi.org/10.1136/jitc-2023-008722
nct03665129 at ClinicalTrials.govDocuments that mention this clinical trial
Neutrophils in the era of immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-002242
nct02922764 at ClinicalTrials.govDocuments that mention this clinical trial
Complement system in cancer: friend or foe of immunotherapy
https://doi.org/10.1136/jitc-2025-013290
Neutrophils in the era of immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-002242
nct03681951 at ClinicalTrials.govDocuments that mention this clinical trial
Myeloid metabolism and its role in immunotherapy of cancer
https://doi.org/10.1136/jitc-2025-012127
Neutrophils in the era of immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-002242
Documents that mention this clinical trial
Neutrophils in the era of immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-002242
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb Foundation
Fondation ARC pour la Recherche sur le Cancer (20191209423)
LabEx MAbImprove
Fondation pour la Recherche Médicale (ARF201809007001)
- License Information
